Dictionaries Armenian-English English-Armenian MeSH Feedback
UMLS. CSP-HL7-ICD9CM-NCI-NDFRT-RXNORM
%
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
F F F- F0 FA FB FC FD FE FF FG FH FI FJ FK FL FM FN FO FP FR FS FT FU FX FY
selected terms: 2,504
 1 ▫ 2 ▫ 3 ▫ 4 ▫ .. ▫ 26 ▫ Next >>
 page 1 of 26

1. 1-(3-Furanyl)-4-hydroxy-1-pentanone
[A natural toxic furan isolated from a fungus-infected sweet potato (Ipomoea batatas) with potential antineoplastic activity. Ipomeanol is activated by mixed function oxidases in vivo to its epoxide form, an alkylating agent that covalently binds cell macromolecules. This agent causes cell death by a p53-independent mechanism. (NCI04) ( NCI )] (UMLS (NCI) C0048420) =Organic Chemical; Biologically Active Substance
51. 5-FU/L-PAM
(UMLS (NCI) C0279387) =Therapeutic or Preventive Procedure
2. 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
[An azetidinone derivative and a cholesterol absorption inhibitor with lipid-lowering activity. Ezetimibe appears to interact physically with cholesterol transporters at the brush border of the small intestine and inhibits the intestinal absorption of cholesterol and related phytosterols. As a result, ezetimibe causes a decrease in the level of blood cholesterol or an increase in the clearance of cholesterol from the bloodstream. Overall, the following effects observed are a reduction of hepatic cholesterol stores and a reduction of total cholesterol, LDL cholesterol, and other triglycerides in the blood. ( NCI )] (UMLS (NCI) C1142985) EZETIMIBE;
EZETIMIBE PREPARATION =Organic Chemical; Pharmacologic Substance ;
=[CV350] ANTILIPEMIC AGENTS;
Unclassified Ingredients =EZETIMIBE 10 MG;
52. 5-FU/L-PAM/TMX
(UMLS (NCI) C0279232) =Therapeutic or Preventive Procedure ;
3. 1-fluoro-2,4-dinitrobenzene
[Irritants and reagents for labeling terminal amino acid groups. ( MSH )] (UMLS (NCI) C0012463) =Organic Chemical; Indicator, Reagent, or Diagnostic Aid ;
53. 5-FU/LEV
(UMLS (NCI) C0279296) =Therapeutic or Preventive Procedure ;
4. 1-Fluoroethene
[A synthetic, colorless gas that is insoluble in water and soluble in organic solvents. It is used primarily in the production of polyvinyl fluoride and other fluoropolymers. Vinyl fluoride is extremely flammable and emits highly toxic hydrogen fluoride gas when burned. Vinyl fluoride metabolites form covalent DNA adducts that attribute to inhibition of DNA replication and to mutagenicity consequences. It is reasonably anticipated to be a human carcinogen. (NCI05) ( NCI )] (UMLS (NCI) C0078265) =Organic Chemical; Hazardous or Poisonous Substance ;
54. 5-FU/LEV/MOAB 17-1A
(UMLS (NCI) C0338293) =Therapeutic or Preventive Procedure
5. 10% Formalin
(UMLS (HL7) C1550067) =Organic Chemical; Biomedical or Dental Material ;
=Additive/Preservative;
55. 5-FU/MeCCNU
(UMLS (NCI) C0280524) =Therapeutic or Preventive Procedure
6. 10% Formalin
[A 10% v/v solution in water of formalin( a 37% solution of formaldehyde and water). Used for tissue preservation. ( HL7V3.0 )] (UMLS (HL7) C1561470) =Intellectual Product =MaterialEntityAdditive;
56. 5-FU/MeCCNU/SZC/VCR
(UMLS (NCI) C0066687) =Therapeutic or Preventive Procedure ;
7. 14-3-3 Family
[The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. Two different binding motifs, RSXpSXP and RXY/FXpSXP, are present in nearly all known 14-3-3 binding proteins. The14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and Cbl. (from OMIM) ( NCI )] (UMLS (NCI) C1337047) =Amino Acid, Peptide, or Protein; Biologically Active Substance
57. 5-FU/MeCCNU/VCR
(UMLS (NCI) C0066686) =Therapeutic or Preventive Procedure ;
8. 18F-FHBG
[A fluorine-18 labeled acycloguanosine derivative and a reporter probe with imaging activity. Used in conjunction with adenoviral gene transfer system containing report gene for herpes simplex virus type 1 thymidine kinase (HSV1-TK), 18F-FHBG can be phosphorylated by this enzyme, thereby accumulating in the adenoviral transfected cells. This allows for assessment of transfection tissue location and efficiency of gene transfer. ( NCI )] (UMLS (NCI) C0754974) 9-(4-18F-Fluoro-3-[hydroxymethyl]butyl)guanine;
Reporter Probe 18F-FHBG;
=Nucleic Acid, Nucleoside, or Nucleotide
58. 5-FU/MITO
(UMLS (NCI) C0279374) =Therapeutic or Preventive Procedure
9. 18FDG
[The radioactive form of glucose used in positron emission tomography (PET), a diagnostic imaging procedure. ( NCI )] (UMLS (NCI) C0046056) =Organic Chemical; Indicator, Reagent, or Diagnostic Aid ;
59. 5-FU/MITO/MTX
(UMLS (NCI) C0278904) =Therapeutic or Preventive Procedure
10. 2'-Fluoro-2',3'-Dideoxyadenosine
[A fluoro-substituted analog of dideoxyadenosine that inhibits reverse transcriptase, thereby inhibiting telomerase activity and subsequent cell proliferation. ( NCI )] (UMLS (NCI) C0220150) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
60. 5-FU/MITO/SZC
(UMLS (NCI) C0082637) =Therapeutic or Preventive Procedure
11. 2-F-ara-AMP
[The phosphate salt of fludarabine, a synthetic purine nucleoside antimetabolite with antineoplastic activity. Preferentially transported into malignant cells and metabolized to its active form 2-fluoro-ara-ATP by deoxycytidine kinase, fludarabine inhibits alpha DNA polymerase and RNA reductase and competes with deoxyadenosine triphosphate, resulting in inhibition of DNA primase, inhibition of DNA synthesis, and cell death. (NCI04) ( NCI )] (UMLS (NCI) C0060483) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance =2-Fluoro-9-beta-arabinofuranosyladenine;
=FLUDARABINE PHOSPHATE 50 MG;
61. 5-FU/MITO/VCR
(UMLS (NCI) C0060627) =Therapeutic or Preventive Procedure ;
12. 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene
(UMLS (NCI) C0767920) =Organic Chemical; Pharmacologic Substance ;
62. 5-FU/MMPR/PALA
(UMLS (NCI) C0278682) =Therapeutic or Preventive Procedure
13. 2-Fluoro-9-beta-arabinofuranosyladenine
[nucleoside analog used alone or in combination with other agents to treat various cancers, especially leukemia. ( CSP )] (UMLS (NCI) C0059985) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance =[AN300] ANTINEOPLASTICS, ANTIMETABOLITES;
[AN000] ANTINEOPLASTICS;
9-Beta-D-arabinofuranosyl-9H-purine-6-amine Monohydrate;
adenine nucleoside;
nucleoside analog;
=2-F-ara-AMP;
63. 5-FU/MTX
(UMLS (NCI) C0280603) =Therapeutic or Preventive Procedure
14. 2-Fluoro-alpha-methyl-4-diphenylacetic Acid Sodium Salt
[The sodium salt form of flurbiprofen, a propionic acid derivative and a member of the phenylalkanoic acid group of non-steroidal antiinflammatory drugs (NSAIDs) with analgesic, antiinflammatory and antipyretic effects. Flurbiprofen non-selectively binds to and inhibits cyclooxygenase (COX). This results in a reduction of arachidonic acid conversion into prostaglandins that are involved in the regulation of pain, inflammation and fever. This NSAID also inhibits carbonic anhydrase, thereby reducing the production of hydrogen and bicarbonate ions. Upon ocular administration, flurbiprofen may reduce bicarbonate ion concentrations leading to a decrease in the production of aqueous humor, thereby lowering intraocular pressure. ( NCI )] (UMLS (NCI) C0304658) =Organic Chemical; Pharmacologic Substance ;
=2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid;
[OP900] OPHTHALMICS, OTHER =FLURBIPROFEN SODIUM 0.03 %;
64. 5-FU/MTX/PALA
(UMLS (NCI) C0280516) =Therapeutic or Preventive Procedure ;
15. 2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid
[A derivative of propionic acid, and a phenylalkanoic acid derivative of non-steroidal antiinflammatory drugs (NSAIDs) with analgesic, antiinflammatory and antipyretic effects. Flurbiprofen non-selectively binds to and inhibits cyclooxygenase (COX). This results in a reduction of arachidonic acid conversion into prostaglandins that are involved in the regulation of pain, inflammation and fever. This NSAID also inhibits carbonic anhydrase, thereby reducing the production of hydrogen and bicarbonate ions. Upon ocular administration, flurbiprofen may reduce bicarbonate ion concentrations leading to a decrease in the production of aqueous humor, thereby lowering intraocular pressure. ( NCI )] (UMLS (NCI) C0016377) =Organic Chemical; Pharmacologic Substance ;
=Propionic Acids;
[MS102] NONSALICYLATE NSAIS, ANTIRHEUMATIC =2-Fluoro-alpha-methyl-4-diphenylacetic Acid Sodium Salt;
FLURBIPROFEN 100 MG;
FLURBIPROFEN 50 MG;
65. 5-FU/MTX/PRED/TSPA/VBL
(UMLS (NCI) C0279275) =Therapeutic or Preventive Procedure ;
16. 2F1
[Encoded by human SLC25A5 Gene (Mitochondrial Carrier Family), 298-aa 33-kDa homodimeric integral membrane protein Adenine Nucleotide Translocator-2 contains 3 Solcar repeats and catalyzes ADP/ATP exchange of across the inner mitochondrial membrane. ANT2 facilitates ADP/ATP exchange between the cytosol and mitochondria. The mitochondrial permeability transition pore (mtPTP) complex, which includes ANT, mediates sudden increase in inner mitochondrial membrane permeability common in apoptosis. ( NCI )] (UMLS (NCI) C1442882) Adenine Nucleotide Translocator-2;
ADP-ATP Translocase-2;
Fibroblast Adenine Nucleotide Translocator-2;
Fibroblast ADP-ATP Carrier Protein;
Mitochondrial Adenine Nucleotide Translocator Solute Carrier Family 25 Member-5;
Solute Carrier Family 25 Member-5;
T2;
T3;
=Amino Acid, Peptide, or Protein; Biologically Active Substance
66. 5-FU/MTX/TMX
(UMLS (NCI) C0279041) =Therapeutic or Preventive Procedure
17. 3-(4-(1-formylpiperazin-4-yl)-benzylidenyl)-2-indolinone
(UMLS (NCI) C0538432) =Organic Chemical; Pharmacologic Substance
67. 5-FU/MTX/TMX/TSPA
(UMLS (NCI) C0280700) =Therapeutic or Preventive Procedure
18. 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4[1H,3H]-quinazolinedione
[3-(2-(4-(p-fluorobenzoyl)-piperidino) ethyl)-2,4-quinazolinedione. ( CSP )] (UMLS (NCI) C0022616) =Organic Chemical; Pharmacologic Substance =quinazoline;
serotonin inhibitor
68. 5-FU/MTX/TSPA
(UMLS (NCI) C0244554) =Therapeutic or Preventive Procedure
19. 309 F
(UMLS (NCI) C0878169) Fourneau 309 =Organic Chemical; Pharmacologic Substance
69. 5-FU/MTX/VBL
(UMLS (NCI) C0279825) =Therapeutic or Preventive Procedure
20. 3F8
[A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells. ( NCI )] (UMLS (NCI) C0280849) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
70. 5-FU/MTX/VCR
(UMLS (NCI) C0078399) =Therapeutic or Preventive Procedure
21. 5 fluorodeoxycytidine
[ ] (UMLS (CSP) C0597703) =Nucleic Acid, Nucleoside, or Nucleotide; Biologically Active Substance =deoxycytidine;
halocarbon compound;
nucleoside analog;
71. 5-FU/PALA
(UMLS (NCI) C0280504) =Therapeutic or Preventive Procedure ;
22. 5 fluorouridine
[uridine analogs; 18F-labeled compound. ( CSP )] (UMLS (CSP) C0049192) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance =deoxyuridine;
fluoropyrimidine;
halocarbon compound;
nucleoside analog
72. 5-FU/PBA
(UMLS (NCI) C0392930) =Therapeutic or Preventive Procedure ;
23. 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione
[An anticancer drug that belongs to the family of drugs called antimetabolites. ( NCI )] (UMLS (NCI) C0016778) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
73. 5-FU/PRED/VCR
(UMLS (NCI) C0279786) =Therapeutic or Preventive Procedure
24. 5-Fluoro-2-Deoxycytidine
[An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted intracellularly, by deaminases, to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate leading to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth. ( NCI )] (UMLS (NCI) C0049174) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
74. 5-FU/SMS 201-995 pa
(UMLS (NCI) C0338277) =Therapeutic or Preventive Procedure ;
25. 5-Fluoropyrimidinone
[A fluoronucleoside that inhibits pyrimidine synthesis, interfering with DNA synthesis. ( NCI )] (UMLS (NCI) C0393034) =Organic Chemical; Pharmacologic Substance ;
75. 5-FU/SZC
(UMLS (NCI) C0278920) =Therapeutic or Preventive Procedure
26. 5-Fluorouracil/epi
[An injectable collagen matrix gel containing the antimetabolite fluorouracil and the symhathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with uracil during RNA synthesis whereas another active metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate inhibits thymidylate synthase, thereby interfering with DNA synthesis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of fluorouracil into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of fluorouracil and increasing its anti-tumor activity. Intratumoral injection of fluorouracil combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects. ( NCI )] (UMLS (NCI) C0281426) =Clinical Drug
76. 5-FU/TAU
(UMLS (NCI) C0281354) =Therapeutic or Preventive Procedure
27. 5-Formyl Tetrahydrofolate
(UMLS (NCI) C0520456) =Organic Chemical; Vitamin ;
77. 5-FU/TAX
(UMLS (NCI) C0678091) =Therapeutic or Preventive Procedure
28. 5-Formyl-5,6,7,8-tetrahydrofolic Acid
[USP lists as an antidote to folate antagonists and an agent for treatment of folate deficiency anemias. ( CSP )] (UMLS (NCI) C0023413) =Organic Chemical; Pharmacologic Substance; Vitamin =formyltetrahydrofolate;
folacin;
[VT102] FOLIC ACID/LEUCOVORIN;
=Calcium (6S)-Folinate;
78. 5-FU/TMTX
(UMLS (NCI) C0678039) =Therapeutic or Preventive Procedure ;
29. 5-FU/FUDR
(UMLS (NCI) C0280815) =Therapeutic or Preventive Procedure ;
79. 5-FU/TXT
(UMLS (NCI) C0677975) =Therapeutic or Preventive Procedure
30. 5-FU/G-CSF/HU/IFN-A
(UMLS (NCI) C0338187) =Therapeutic or Preventive Procedure ;
80. 5-FU/VNB
(UMLS (NCI) C0281257) =Therapeutic or Preventive Procedure ;
31. 5-FU/G-CSF/IFN-A
(UMLS (NCI) C0338151) =Therapeutic or Preventive Procedure
81. 5-FU/VP-16
(UMLS (NCI) C0281647) =Therapeutic or Preventive Procedure ;
32. 5-FU/GAN
(UMLS (NCI) C0281382) =Therapeutic or Preventive Procedure ;
82. 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide)
(UMLS (NCI) C1176020) Sunitinib =Organic Chemical; Pharmacologic Substance
33. 5-FU/HMM/MITO
(UMLS (NCI) C0279184) =Therapeutic or Preventive Procedure
83. 5FU/Leucovorin
(UMLS (NCI) C0278707) =Therapeutic or Preventive Procedure
34. 5-FU/HU
(UMLS (NCI) C0280678) =Therapeutic or Preventive Procedure
84. 5FU/Leucovorin/Gemcitabine
(UMLS (NCI) C0677790) =Therapeutic or Preventive Procedure
35. 5-FU/HU/IFN-A
(UMLS (NCI) C0338175) =Therapeutic or Preventive Procedure
85. 5FU/Leucovorin/Irinotecan
(UMLS (NCI) C0281534) =Therapeutic or Preventive Procedure
36. 5-FU/HU/IUDR
(UMLS (NCI) C0280826) =Therapeutic or Preventive Procedure
86. 5FU/Leucovorin/Levamisole
(UMLS (NCI) C0278901) =Therapeutic or Preventive Procedure
37. 5-FU/HU/TAX
(UMLS (NCI) C0393082) =Therapeutic or Preventive Procedure
87. 6-Fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic Acid
[A synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04) ( NCI )] (UMLS (NCI) C0280509) =Organic Chemical; Pharmacologic Substance
38. 5-FU/ICI D1694
(UMLS (NCI) C0677774) =Therapeutic or Preventive Procedure
88. 9-Fluoro-11-beta,21-dihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione
[A synthetic glucocorticoid receptor agonist with metabolic, anti-inflammatory and immunosuppressive activity. Desoximetasone activates specific intracellular receptors, which bind to distinct sites on DNA to modify gene transcription. This results in an induction of the synthesis of anti-inflammatory proteins and suppression of the synthesis of inflammatory mediators. This leads to an overall reduction in chronic inflammation and autoimmune reactions. Desoximetasone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ( NCI )] (UMLS (NCI) C0011707) =Steroid; Pharmacologic Substance; Hormone =(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione;
Pregnadienediols;
[DE200] ANTI-INFLAMMATORY, TOPICAL;
=DESOXIMETASONE 0.25 %;
DESOXIMETASONE 0.5 %;
DESOXIMETASONE 0.05 %
39. 5-FU/ICRF-159/MeCCNU
(UMLS (NCI) C0279362) =Therapeutic or Preventive Procedure
89. 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 17-acetate
[The acetate salt form of fluorometholone, a synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Fluorometholone acetate exerts its effect by interacting with cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions. ( NCI )] (UMLS (NCI) C0724587) Fluorometholone Acetate;
FLUOROMETHOLONE ACETATE PREPARATION =Steroid; Pharmacologic Substance ;
=FLUOROMETHOLONE;
=FLUOROMETHOLONE ACETATE 0.1 %;
40. 5-FU/IFN-A
(UMLS (NCI) C0338085) =Therapeutic or Preventive Procedure
90. F
[Maxillary left central primary incisor ( HL7V3.0 )] (UMLS (HL7) C1533615) =Body Part, Organ, or Organ Component; ;
=Primary dentition;
◊ [Used to describe the quotient of two c2 random variables. The F-distribution has two parameters n1 and n2, which are the numbers of degrees of freedom of the numerator and denominator variable respectively. The relationship to mean m and variance s2 are: m = n2 / (n2 - 2) and s2 = (2 n2 (n2 + n1 - 2)) / (n1 (n2 - 2)2 (n2 - 4)). ( HL7V3.0 )] (UMLS (HL7) C1552648) Qualitative Concept ProbabilityDistributionType;
41. 5-FU/IFN-A/IL-2
(UMLS (NCI) C0338141) =Therapeutic or Preventive Procedure
91. F
[use in conjunction with a disease, disorder, dysfunction, body system, or function which is gender specific. ( CSP )] (UMLS (NCI) C0015780) =Organism Attribute ;
=gender;
Sex;
AdministrativeGender;
Administrative Sex ◊ [nonmetallic, diatomic gas, symbol F, atomic number 9, atomic weight 18.998, that is a trace element and member of the halogen family. ( CSP )] (UMLS (NCI) C0016330) Biologically Active Substance; Hazardous or Poisonous Substance; Element, Ion, or Isotope halogen;
42. 5-FU/IFN-A/MITO
(UMLS (NCI) C0338093) =Therapeutic or Preventive Procedure
92. F
[The SI unit of capacitance equal to the capacitance of a capacitor having an equal and opposite charge of one coulomb on each plate and a potential difference of one volt between the plates. ( NCI )] (UMLS (NCI) C0582515) =Quantitative Concept ;
=UnitOfMeasureAtomInsens;
UnitOfMeasureAtomSens
43. 5-FU/IFN-A/PALA
(UMLS (NCI) C0338107) =Therapeutic or Preventive Procedure ;
93. F 1686
(UMLS (NCI) C0164083) =Organic Chemical; Pharmacologic Substance ;
44. 5-FU/IFN-B
(UMLS (NCI) C0279438) =Therapeutic or Preventive Procedure
94. F factor
[A plasmid whose presence in the cell, either extrachromosomal or integrated into the BACTERIAL CHROMOSOME, determines the "sex" of the bacterium, host chromosome mobilization, transfer via conjugation (CONJUGATION, GENETIC) of genetic material, and the formation of SEX PILI. ( MSH )] (UMLS (CSP) C0015435) =Nucleic Acid, Nucleoside, or Nucleotide; Biologically Active Substance
45. 5-FU/IL-1B
(UMLS (NCI) C0280480) =Therapeutic or Preventive Procedure ;
95. F Test
[A test of the hypothesis that the standard deviations of two normally distributed populations are equal, and thus that they are of comparable origin. ( NCI )] (UMLS (NCI) C0870536) F-Test =Intellectual Product ;
46. 5-FU/IUDR
(UMLS (NCI) C0278672) =Therapeutic or Preventive Procedure
96. F- element
[anion of fluorine. ( CSP )] (UMLS (CSP) C0677517) =Element, Ion, or Isotope ;
=ion;
47. 5-FU/L-CF
(UMLS (NCI) C0280780) =Therapeutic or Preventive Procedure
97. F-actin
(UMLS (NCI) C1180307) Filamentous Actin =Amino Acid, Peptide, or Protein; Biologically Active Substance
48. 5-FU/L-CF/LEV
(UMLS (NCI) C0281741) =Therapeutic or Preventive Procedure
98. F-box and WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila) Gene
[This gene is involved in ubiquitin-dependent proteolysis and regulation of the G1-S cell cycle checkpoint. ( NCI )] (UMLS (NCI) C1333533) FBXW7;
FBXW7 Gene =Gene or Genome ;
49. 5-FU/L-CF/MTX
(UMLS (NCI) C0281749) =Therapeutic or Preventive Procedure
99. F-SRC-1
[Nuclear Receptor Coactivator 1 is a co-activator for the full transcriptional activity of ligand-activated PGR, ESR, GRL, THR, and RXRA through their DNA response elements. SRC1 can also enhance the transcriptional activity of SP1, but not E2F, E47, or CREB. SRC1 has a glutamine-rich and a serine/threonine-rich region. SRC1 can also bind to TBP and to TFIIB, in addition to nuclear hormone receptors in a ligand-dependent manner; SRC1 may bridge nuclear hormone receptors with general transcription factors. Studies suggest a dual role for SRC1 in chromatin remodeling and in recruitment/stabilization of general transcription factors. (from OMIM 602691 and NCI) ( NCI )] (UMLS (NCI) C0384189) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
50. 5-FU/L-OHP
(UMLS (NCI) C0796511) Fluorouracil/Oxaliplatin =Therapeutic or Preventive Procedure
100. F1 hybrid disease
[ ] (UMLS (CSP) C0598534) =Disease or Syndrome ;

Buy website

Medical Clinic. Optician. Pharmacy. Physician. Travel Agency. Hotel reservation. Child Care. Education. Teachers. Lessons. Tests and Exams. Certification. Shopping Center. Store. Real Estate.
Affordable prices from $100.

 home Dictionaries Armenian-English English-Armenian MeSH Feedback  top
© 2008 -2011 Administrator MEDINDEX.AM